SABS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Stats
Tagesvolumen	2 678.00
Durchschnittsvolumen	13 575.00
Marktkapitalisierung	38.65M
EPS	$0 ( 2024-04-01 )
Nächstes Ertragsdatum	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.550
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Kropotova Alexandra	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	Sullivan Eddie Joe	Buy	190 000	Employee Stock Option (right to buy)
2024-02-21	Bausch Christoph Lawrence	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	King Michael	Buy	115 000	Employee Stock Option (right to buy)
2024-02-21	Reich Samuel J	Buy	434 000	Employee Stock Option (right to buy)

INSIDER POWER
70.14
Last 88 transactions
Buy: 19 783 333 \| Sell: 3 137 658

SAB Biotherapeutics, Inc. Korrelation

10 Am meisten positiv korreliert
SHBI	0.924
RXT	0.912
POTX	0.907
MVST	0.905
WSBC	0.902
VNDA	0.9
BCAB	0.9
SPFI	0.899
OPHC	0.898
UCBI	0.897

10 Am meisten negativ korreliert
RMRM	-0.93
APOP	-0.915
IIN	-0.882
EXFO	-0.881
TIG	-0.874
MLVF	-0.873
AUPH	-0.872
EVCM	-0.871
SUMR	-0.871
CARG	-0.869

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

SAB Biotherapeutics, Inc. Finanzdaten

Annual	2023
Umsatz:	$2.24M
Bruttogewinn:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2023
Umsatz:	$2.24M
Bruttogewinn:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2022
Umsatz:	$23.90M
Bruttogewinn:	$20.61M (86.23 %)
EPS:	$-4.31

FY	2021
Umsatz:	$60.88M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.394

Financial Reports:

No articles found.

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.